Modeling ALS Pathophysiology Using Patient-Derived iPSCs for Therapeutic Insights
Time: 10:30 am
day: Conference Day One Track A
Details:
- Establishing patient-derived iPSC-neurons harboring TDP-43 mutations, providing a robust in vitro model to recapitulate key pathological features of ALS
- Comprehensive analyses to investigate the mechanisms of action of currently available ALS therapies, offering deeper insights into their therapeutic impact
- Identifying novel drug targets, paving the way for the development of innovative treatments for ALS
